(NASDAQ: ETON) Eton Pharmaceuticals's forecast annual revenue growth rate of 76.46% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Eton Pharmaceuticals's revenue in 2025 is $35,947,000.On average, 2 Wall Street analysts forecast ETON's revenue for 2025 to be $2,174,245,748, with the lowest ETON revenue forecast at $1,694,854,982, and the highest ETON revenue forecast at $2,653,636,513. On average, 2 Wall Street analysts forecast ETON's revenue for 2026 to be $3,801,539,057, with the lowest ETON revenue forecast at $2,702,466,938, and the highest ETON revenue forecast at $4,900,611,175.
In 2027, ETON is forecast to generate $5,037,672,237 in revenue, with the lowest revenue forecast at $3,238,568,171 and the highest revenue forecast at $6,836,776,302.